Results 1 to 10 of about 44,177 (299)
Haematologica, 2017 Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no consensus on the optimal graft-versus-host disease prophylaxis.
Annalisa Ruggeri +17 more
doaj +1 more source
Breakdown of thymic tolerance - an etiologic link between acute and chronic graft-versus-host disease [PDF]
, 2014 Allogeneic haematopoietic stem cell transplantation (HSCT) is the standard therapy for many disorders of the haematological system. Its use is limited by the major complication acute graft-versus-host disease (GVHD). Development of acute GVHD predisposes
Dertschnig, Simone
core +1 more source
Korean Journal of Transplantation, 2023 Background : Graft-versus-host disease (GVHD) is a rare, but potentially fatal complication of liver transplantation. One-way human leukocyte antigens (HLA) mismatch has emerged as a risk factor for GVHD.
Seung Hyuk Yim +4 more
doaj +1 more source
Frontiers in Immunology, 2017 BackgroundGraft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the ...
Aude Burlion +4 more
doaj +1 more source
Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]
, 2003 Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Kolb, Hans-Jochem +8 more
core +1 more source
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Frontiers in Immunology, 2020 Graft-versus-host disease (GvHD) remains the second leading cause of death in allogeneic hematopoietic stem cell transplantation recipients, highlighting the need for improved preventative strategies.
Megan S. Molina +14 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2018 Background: Hematopoietic stem cell transplantation is a curative treatment for many patients with hematological disorders. Donor–recipient genetic disparity, especially involving the human leukocyte antigen system is a critical factor for transplant ...
Alessandra Paz +12 more
doaj +1 more source
Frontiers in Oncology, 2021 Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances.
Justin Loke +5 more
doaj +1 more source
International Journal of Medical Students, 2023 BACKGROUND: Graft-versus-host disease (GVHD) continues to compromise the overall success of allogenic hematopoietic stem cell transplantation. It is the most important cause of morbidity and non-relapse mortality after allogeneic hematopoietic stem cell
Fernando Tienda-López +4 more
doaj +1 more source